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Abstract 
Background: General anaesthesia (GA) during endovascular thrombectomy 
has been associated with worse patient outcomes in observational studies. 
We examined the association between GA and functional outcome in 
ischaemic stroke patients with large vessel anterior circulation occlusion 
undergoing endovascular thrombectomy versus standard care in pooled data 
from available trials. 
Methods: Patient-level data were pooled from randomised trials listed in 
Pubmed 1/Jan/2010-31/May/2017 comparing endovascular thrombectomy 
performed using predominantly stent-retrievers with standard care in anterior 
circulation ischaemic stroke patients (HERMES Collaboration). The primary 
outcome was ordinal analysis of the modified Rankin scale (mRS) at 90 days 
in the GA and non-GA subgroups of endovascular-treated patients and 
patients randomised to standard care, adjusted for baseline prognostic 
variables. An alternative approach using propensity-score stratification was 
also used. To account for between-trial variance we used mixed-effects 
modeling with a random effect for trial incorporated in all models. Bias was 
assessed using the Cochrane tool. 
Findings: Of 1764 patients in 7 trials, 871 were allocated to endovascular 
thrombectomy. After exclusion of 74 patients (72 who did not undergo the 
procedure and 2 with missing data on anaesthetic strategy), 236/797 (30%) of 
endovascular patients were treated under GA. At baseline, GA patients were 
younger and had shorter time to randomisation but similar pre-treatment 
clinical severity compared to non-GA. Endovascular thrombectomy improved 
functional outcome at 3 months versus standard care in both GA (adjusted 
common odds ratio (cOR) 1·52, 95%CI 1·09-2·11, p=0·014) and non-GA 
(adjusted cOR 2·33, 95%CI 1·75-3·10, p<0·001) patients. However, 
outcomes were significantly better for those treated under non-GA versus GA 
(covariate-adjusted cOR 1·53, 95%CI 1·14-2·04, p=0·004; propensity-
stratified cOR 1·44 95%CI 1·08-1·92, p=0·012). The risk of bias and variability 
among studies was assessed to be low. 
Interpretation: Worse outcomes after endovascular thrombectomy were 
associated with GA, after adjustment for baseline prognostic variables. These 
data support avoidance of GA whenever possible. The procedure did, 
however, remain effective versus standard care in patients treated under GA, 
indicating that treatment should not be withheld in those who require 
anaesthesia for medical reasons.  
Funding: The HERMES collaboration was funded by an unrestricted grant 
from Medtronic to the University of Calgary. 
 
Research in context 
Evidence before this study 
We searched Pubmed for studies examining the association of general 
anaesthesia with outcome in stroke patients undergoing endovascular 
thrombectomy between 1 Jan 2010 and 31 May 2017. Multiple observational 
studies demonstrated worse outcome in patients treated under general 
anaesthesia. Individual randomised trials of thrombectomy versus standard 
care found conflicting results on the effect of general anaesthesia, varying 
between abolition of the thrombectomy treatment effect in MR CLEAN and no 
effect in THRACE. Three single-centre randomised trials of general 
anaesthesia versus conscious sedation found either no difference in 
functional outcome between groups or a slight benefit of general anaesthesia.    
 
 
Added value of this study 
These data from contemporary, high quality randomised trials form the largest 
study to date of the association between general anesthesia and the benefit of 
endovascular thrombectomy versus standard care. We used two different 
approaches to adjust for baseline imbalances (multivariable logistic regression 
and propensity-score stratification). We found that GA for endovascular 
thrombectomy, as practiced in contemporary clinical care across a wide range 
of expert centres during the randomised trials, was associated with worse 
outcome than avoiding GA, independent of patient co-morbidities. Patients 
still benefited from thrombectomy compared to standard care when treated 
under GA.  
 
Implications of all the available evidence 
The requirement for GA due to airway compromise or agitation that threatens 
the quality of revascularization should not deter clinicians from pursuing 
endovascular thrombectomy. The contrast between this analysis and the 
recent randomised trials comparing GA and conscious sedation suggests that, 
when GA is medically necessary, close attention should be paid to minimizing 
anaesthetic delays to commence the procedure and maintaining physiological 
parameters such as blood pressure. A multi-centre randomised trial to 
definitively address these issues is warranted. 
Introduction: 
 
Multiple observational studies have suggested that patients treated with 
endovascular thrombectomy under general anaesthesia (GA) have poorer 
outcomes than those treated without GA.1 However, patients with more 
severe stroke or comorbidities may be more likely to be treated under GA, 
leading to the potential for confounding by indication. In MR CLEAN, sites 
specified their anaesthetic strategy prospectively and analysis of that trial 
found that the beneficial treatment effect of thrombectomy became non-
significant in patients treated under GA.2 These results could lead to a 
reluctance to convert from an awake procedure to GA in cases where patient 
agitation or challenging vascular anatomy are preventing optimal 
revascularization. In contrast, three small single-centre randomised trials 
which compared GA, performed using strict protocols to maintain blood 
pressure, with conscious sedation using the same agents at lower doses 
without intubation did not detect a signal of harm and functional independence 
was either no different or slightly increased in the GA patients.3-5 We analysed 
the pooled individual patient data from available randomised trials to assess 
whether a treatment benefit was preserved in patients treated under GA in 
broader contemporary practice. 
 
  
Methods: 
 
We searched Pubmed for randomised trials published between 1 Jan 2010 
and 31 May 2017 comparing endovascular thrombectomy performed using 
predominantly stent-retrievers with standard care in anterior circulation 
ischaemic stroke patients - Pubmed search string: (("randomized controlled 
trial"[Publication Type]) AND ((thrombectomy[Title/Abstract]) OR (clot 
retrieval[Title/Abstract]) OR intraarterial[Title/Abstract]) AND 
(stroke[Title/Abstract]) AND ("2010/01/01"[Date - Publication] : 
"2017/05/31"[Date - Publication])). The Highly Effective Reperfusion using 
Multiple Endovascular Devices (HERMES) collaboration6 pooled individual 
patient data from the MR CLEAN,7 ESCAPE,8 EXTEND-IA,9 SWIFT PRIME,10 
REVASCAT,11 PISTE12 and THRACE13 trials. All participants provided 
informed consent according to each trial protocol and each study was 
approved by the local ethics board.  
 
This meta-analysis was prospectively designed by the HERMES executive 
committee but not registered. The study protocol is included in the 
supplementary webappendix. Data were contributed by the authors of all the 
trials meeting eligibility criteria and collated by independent statisticians. All 
data relevant to the analyses presented were part of each study’s individual 
design and data collection and are part of the general HERMES database.  
No standardization or translation of the fields employed for analysis and 
reporting was necessary. After collation of data, key fields were compared to 
original results, including published data.  No major discrepancies were found 
and minor discrepancies were resolved in collaboration with the study 
authors/investigators. The study selection process is outlined in 
supplementary Figure SA1. Variability between studies is described in 
supplementary Table SA1 and heterogeneity assessed in supplementary 
figures SA2-4. Risk of bias in the individual studies was assessed using the 
Cochrane handbook methodology14 and was low for all studies except 
THRACE which used unblinded assessment of day 90 functional outcome 
(supplementary Table SA2). The principal risk of bias derived from differences 
among individual studies’ methods and inclusion criteria. A one-stage 
approach was employed, defined as use of individual patient data with 
analysis including covariates and random study effects to appropriately 
incorporate any between-study differences.  
 
In MR CLEAN, the steering committee gave no recommendations about 
anaesthetic management. Nevertheless, the majority of centres adhered to a 
fixed protocol regarding type of anesthetic management throughout the trial. 
In the other trials, the use of anaesthesia was at the discretion of the treating 
team on a case by case basis, although two trials (ESCAPE and REVASCAT) 
discouraged GA where possible. 
 
Patients treated under GA (sedation with intubation) were identified and their 
baseline characteristics compared to the non-GA patients who were managed 
with or without sedation and not intubated.  
 
The primary outcome was the mRS at 3 months, which was analysed using 
ordinal logistic regression to obtain the common odds ratio (cOR). Secondary 
outcomes were the proportion of patients reaching independence (mRS 0-2) 
and return to all usual activities (mRS 0-1) and the proportion with early 
neurological recovery defined as a ≥8 point reduction in National Institutes of 
Health Stroke Scale (NIHSS) or reaching 0-1 at 24 hours. Safety outcomes 
were the proportion of patients who had died at 90 days, the proportion with 
symptomatic intracerebral haemorrhage (SICH, as defined by each trial) and 
the proportion with parenchymal haematoma (PH, intracerebral blood clot with 
mass effect). The proportions of endovascular patients with vessel perforation 
and pneumonia were compared between GA and non-GA groups. 
 
Regression analyses were adjusted for baseline prognostic factors including 
age, sex, NIHSS at baseline, ASPECTS, location of occlusion, treatment with 
intravenous alteplase (yes/no) and time to randomisation. Treatment was 
included as a variable with three levels: defined as GA, non-GA and controls. 
To account for between-trial variance we used mixed-effects modeling with a 
random effect for trial incorporated in all models. In addition, as a sensitivity 
analysis, propensity scores were constructed using logistic regression with 
GA vs no GA as the outcome and employing the same set of baseline 
variables as in the regression models.  Propensities were then incorporated 
into the outcome model for the ordinal modified Rankin scale (mRS) score by 
stratification into five groups.15 
 
 
Role of the funding source 
An unrestricted grant was provided to the University of Calgary by Medtronic 
who had no role in study design, the collection, analysis or interpretation of 
data, the writing of the report or the decision to submit the paper for 
publication. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
 
Results: 
 
In the pooled data of 1764 patients, 871 were randomised to endovascular 
thrombectomy and 893 to standard medical care. After exclusion of 74 
patients (72 who did not undergo the procedure and 2 with missing data on 
anaesthetic strategy), 236/797 (30%) of endovascular patients were treated 
under GA. At baseline, patients treated under GA were younger and had 
shorter time from stroke onset to randomisation than those treated without GA 
(Table 1). Baseline clinical severity (NIHSS) was not significantly different 
between groups. GA was used in 113/394 (29%) of right hemisphere and 
119/392 (30%) of left hemisphere stroke patients (p=0·64). GA patients were 
more likely to receive alteplase and had a lower rate of diabetes mellitus. 
 
Functional and neurological outcome 
At 3 months, the patients who underwent endovascular treatment had 
significantly greater odds of improved functional outcome versus standard 
medical care in covariate-adjusted analysis in both GA (common odds ratio 
[cOR] 1·52 CI95 1·09-2·11, p=0·014) and non-GA (cOR 2·33 CI95 1·75-3·10, 
p<0·001) groups, Table 2, Figure 1. There was no heterogeneity in the effect 
of GA on outcome among studies, although the small numbers limit power for 
this analysis. The odds of improved outcome using non-GA versus GA were 
significantly greater in ordinal analysis of the mRS, after adjustment for 
baseline prognostic factors (cOR 1·53 CI95 1·14-2·04, p=0·004). For every 
100 patients treated under GA versus no GA, 18 patients would have worse 
functional outcome, including 10 who would not achieve functional 
independence. The propensity-stratified analysis generated similar results and 
the common odds ratio for improved outcome for non-GA vs GA was 1·44, 
CI95 1·08-1·92, p=0·012. Secondary outcomes followed similar trends (Table 
2).  
 
Safety 
The rate of SICH did not differ between endovascular patients treated under 
GA, those treated without GA or standard medical care patients. The 90-day 
mortality was 13.4% in non-GA patients versus 17.3% in standard medical 
care (p=0·07) and 17.4% in GA patients (Table 2). Pneumonia occurred in a 
similar proportion of GA versus non-GA patients (11·4% versus 8·4% 
p=0·18), although the reported incidence of pneumonia was significantly 
different among studies (p<0·001), likely indicating differences in definition or 
in capture of adverse events. Vessel perforation occurred in 0.4% GA versus 
1.6% non-GA patients (p=0·30). 
 
 
 
Procedural characteristics and time metrics  
The proportion of patients with successful reperfusion post-procedure 
(modified Treatment in Cerebral Infarction mTICI 2b/3 i.e. reperfusion of 
greater than 50% of the affected territory) did not differ between GA and no 
GA patients (75.1% vs 76.1%, p=0.78). The time interval between 
randomisation and reperfusion was significantly greater in GA versus non-GA 
patients (median 105 vs 85 min, p<0·001). However, there was an imbalance 
in the time from stroke onset to randomisation which was median 5 minutes 
shorter in the GA group (p=0·04) and the difference in total onset to 
reperfusion time between both groups was therefore not significant (median 
302 vs 288 min, p=0·57, Table 1). 
 
 
 
Discussion 
 
Patients treated under GA suffered poorer outcomes compared to those 
treated without GA, after adjustment for baseline characteristics. The 
magnitude of this effect was clinically significant – for every 100 patients 
treated under GA versus no GA, 18 patients would have worse functional 
outcome, including 10 who would not achieve functional independence 
However, a significant benefit of endovascular thrombectomy over standard 
care was retained in those patients treated under GA.  
 
The randomised trials differed in their proportion of patients treated under GA 
but the experience in REVASCAT and ESCAPE, which discouraged GA, was 
that <10% of anterior circulation stroke patients had an absolute requirement 
for GA. MR CLEAN has previously reported that GA was associated with 
marked attenuation of treatment effect.2 It is possible that the lower rate of 
revascularization in MR CLEAN attenuated the potential treatment benefit 
compared to EXTEND-IA and SWIFT PRIME. However, the THRACE trial 
reported no difference in outcomes in patients treated with or without GA 
despite a similar effect size to MR CLEAN.13 
 
The method of GA in these randomised trials was entirely at the discretion of 
the treating team and there were no formal protocols specifying anaesthetic 
agents, blood pressure targets or other aspects of physiological management. 
This is in contrast to the highly protocol-specified approach to both GA and 
conscious sedation in the SIESTA, ANSTROKE and GOLIATH trials.3-5 In 
particular, strict attention to maintaining systolic blood pressure >140mmHg 
throughout the procedure (including during anaesthetic induction) may have 
been critical to preserving collateral blood flow to the ischaemic penumbra 
and preventing a harmful effect of GA. There were also specified criteria to 
prevent hyper or hypoventilation.  
 
Each of the GA vs conscious sedation randomised trials also used the same 
medications in both treatment arms, the difference being lower dose and 
absence of intubation in the conscious sedation group. This contrasts with the 
HERMES non-GA patient group, in which treatment varied between no 
sedative medication at all and use of sedatives and anaesthetic agents but 
without intubation. The use of local anaesthetic agent at the arterial puncture 
site without any sedative agent, which is routine at many institutions, may 
have different implications for patient outcome compared to conscious 
sedation as described in the recent randomised trials. Different anaesthetic 
agents could also vary in their protective or harmful effects on ischaemic 
brain, among other hypothetical differences between approaches.16 The 
details of the medications given in the HERMES patients were not available 
for this analysis. 
 
Although the main reasons given for using GA are procedural safety and 
securing the airway, there was no significant difference in the rate of vessel 
perforation or pneumonia between GA and non-GA patients. Our data 
therefore do not support GA as a safer approach to treatment and 
demonstrate the general technical safety of endovascular thrombectomy.  
There are potential advantages of avoiding GA, including the ability to assess 
neurological status during the procedure, reduced intensive care requirements 
post-procedure and reduced costs. In the HERMES trials, GA was also 
associated with a delay in reperfusion. However, this was not the case in the 
randomised trials where a slight delay to start the procedure in GA patients 
(on average  <10 minutes) appeared to be offset by shorter procedural time. 
This may be plausible if reduced patient movement allows more efficient 
roadmap techniques. However, the three centres that performed the 
randomised trials of GA achieved exceptionally fast anaesthetic induction that 
may not be common practice at most institutions. 
  
The main limitation of this study is that the choice to use GA versus non-GA 
was not randomised and the differentiation between medically required GA 
versus elective GA was not recorded in the trial databases. The important 
prognostic variables of age and time from stroke onset to randomisation 
favoured the GA group. We used two different methods of adjustment for 
baseline imbalances (multivariate regression and propensity-score 
stratification) which gave consistent results. Nonetheless, for both methods 
the possibility of unmeasured confounding remains. The anaesthetic practices 
in the HERMES trials were not pre-specified by protocol nor recorded in detail 
but are likely to have been substantially more variable than the recent single 
centre randomised trials comparing GA versus no GA. However, this also 
represents a strength of our study as results are likely to be generalizable to 
current clinical practice. The risk of bias in component trials was overall 
assessed to be low. 
 
In conclusion, the HERMES data suggest that GA for endovascular 
thrombectomy, as practiced in contemporary clinical care across a wide range 
of expert centres during the randomised trials, is associated with worse 
outcome compared to avoiding GA, independent of patient co-morbidities. 
Patients still benefited from thrombectomy compared to standard care when 
treated under GA. Therefore, the requirement for GA due to airway 
compromise or agitation that threatens the quality of revascularization should 
not deter clinicians from pursuing endovascular thrombectomy. The contrast 
between the HERMES data and the recent randomised trials comparing GA 
and conscious sedation suggests that, when GA is medically necessary, close 
attention should be paid to minimizing anaesthetic delays to commence the 
procedure and maintaining physiological parameters such as blood pressure. 
A multi-centre randomised trial to definitively address these issues is 
warranted.  
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Figure 1 – Distribution of modified Rankin Scale at 3 months in patients 
treated under general anaesthesia versus without general anaesthesia (no 
GA) versus the standard medical care group.  
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Table 1 – Baseline characteristics of endovascular patients treated under general anaesthesia 
(GA) versus without GA (no GA) and those who received standard care. 
Characteristic GA (n=236) No GA (n=561) 
 
p-value 
GA vs no 
GA 
All 
Endovascular 
(n=871) 
All Standard 
Care (n=893) 
Age, mean (SD) 63·8 (14) 66·3 (13·3) 0·015 65·5 (13·5) 65·7 (13·5) 
Female sex % (n) 42·8% (101/236) 48·7% (273/561) 0·14 47·3% (412/871) 47·3% (421/891) 
NIHSS at baseline, median 
(IQR) 
18 (15-21) 17 (14-20) 0·09 17 (14-20) 17 (13-21) 
ASPECTS, median (IQR) 7 (6-8) 8 (7-9) 0·0005 8 (7-9) 8 (7-9) 
Left hemisphere affected % (n) 51·3% (119/232) 49·3% (273/554) 0·64 49·5% (424/856) 50·2% (442/881) 
Directly admitted to treating 
centre %(n) 
75·4% (178/236) 77·3% (432/559) 0·57 78·0% (678/869) 75·2% (668/888) 
Onset to randomisation, min 
median (IQR) 
179 (137-238) 184 (144-246) 0·04 181 (141-241) 184 (140-250) 
Randomisation to reperfusion, 
min, median (IQR) 
105 (80-149) 85 (51-118) <0·0001 92 (61-128) NA 
Onset to reperfusion, min 
median (IQR) 
302 (246-357) 288 (222-358) 0·57 291 (231,357) NA 
Site of arterial occlusion      
    ICA occlusion %(n) 25·0% (59/236) 25·7% (144/561)  
0·13 
24·7% (215/871) 25·4% (227/893) 
    M1 occlusion %(n) 59·7% (141/236) 61·1% (343/561) 61·5% (536/871) 60·1% (537/893) 
    M2 occlusion %(n)  6·4% (15/236)  8·4% (47/561)  7·7% (67/871)  7·2% (64/893) 
    Unknown %(n) 8·9% (21/236) 4·8% (27/561)  6·1% (53/871)  7·2% (64/893) 
Alteplase administered %(n) 92·4% (218/236) 84·3% (473/561) 0·002 87·6% (763/871) 90·6% (809/893) 
Hypertension %(n) 50·9% (119/234) 56·1% (315/561) 0·18 53·6% (465/867) 58·8% (523/890) 
Hyperlipidemia %(n) 29·7% (69/232) 36·9% (202/548) 0·06 35·5% (300/846) 40·2% (351/873) 
Diabetes mellitus %(n) 8·9% (21/236) 18·2% (102/560) 0·0009 15·1% (131/867) 17·5% (156/889) 
Smoking %(n) 39·0% (85/218) 36·3% (183/504) 0·503 37·8% (298/788) 36·6% (300/820) 
 
SD standard deviation, IQR interquartile range, NIHSS National Institutes of Health Stroke Scale 
(standardized neurological examination) ranges from normal (0) to death (42). ASPECTS Alberta 
Stroke Program Early Computed Tomography Score (reflects extent of early ischaemic change on CT 
brain: 10 is normal, 0 is involvement of the entire middle cerebral artery territory). ICA internal carotid 
artery, M1 first segment of middle cerebral artery (pre-bifurcation), M2 second segment of middle 
cerebral artery (from bifurcation to the circular sulcus of the insula in the Sylvian fissure). 
Table 2 – Outcomes in patients treated with standard care versus endovascular thrombectomy with or without general anaesthesia (GA)  
Outcome Standard 
Care (n=893) 
Thrombectomy with 
GA (n=236) 
Thrombectomy 
without GA (n=561) 
GA vs Standard * No GA vs Standard *  No GA vs GA * 
Effect size OR 
(95%CI) 
P value Effect size  
OR (95%CI) 
P value Effect size  
OR (95%CI) 
P value 
Primary outcome  
Functional outcome at 90 days (modified 
Rankin Scale – mRS) Ordinal analysis†  – 
median (IQR) – covariate adjusted 
common odds ratio 
 
 
4 (2, 5) 
 
 
3 (2, 4) 
 
 
2 (1, 4) 
 
 
 
1·52 (1·09-2·11) 
 
 
 
0·01 
 
 
 
2·33 (1·75-3·10) 
 
 
 
<0·0001 
 
 
 
1·53 (1·14-2·04) 
 
 
 
0·004 
– propensity-score stratification 
common odds ratio 
   1·42 (1·09-1·84) 0·008 2·21 (1·65-2·95) <0·0001 1·44 (1·08-1·92) 0·01 
Secondary Outcomes 
Independent functional outcome (mRS0-2) 
30·6% 40·2% 50·3% 1·62 (1·16-2·26) 0·005 2·72 (1·99-3·72) <0·0001 1·65 (1·14-2·38) 0·008 
Excellent functional outcome (mRS0-1) 16·6% 22·6% 31·6% 1·53 (1·02-2·31) 0·04 2·72 (2·00-3·69) <0·0001 1·68 (1·12-2·52) 0·01 
Early neurological improvement (NIHSS 
reduction ≥8 points or reaching 0–1 at 
24h) ‡  
23·8% 38·1% 53·2% 2·02 (1·36-3·00 0·0005 3·92 (2·73-5·62) <0·0001 1·75 (1·23-2·48) 0·002 
Safety          
Death within 90 days 17·3% 17·4% 13·4% 1·01 (0·67-1·52) 0·96 0·73 (0·52-1·02) 0·07 0·71 (0·44-1·14) 0·15 
Symptomatic intracerebral haemorrhage§ 3·5% 4·4% 3·8% 1·19 (0·56-2·51) 0·65 1·14 (0·62-2·10) 0·68 0·95 (0·41-2·19) 0·90 
Parenchymal haematoma (PH) 10·2% 14·3% 11·4% 1·38 (0·86-2·22) 0·19 1·25 (0·72-2·16) 0·42 0·97 (0·60-1·58) 0·90 
OR odds ratio, CI confidence interval, IQR interquartile range 
* adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, ASPECTS score, and time from onset to randomisation 
† Modified Rankin scale (mRS) ranges from normal (0) to death (6). Analysis combined mRS 5 & 6  
‡ National Institutes of Health Stroke Scale (NIHSS) score (standardized neurological examination) ranges from normal (0) to death (42), 8 point reduction is highly 
clinically significant.  
§ SICH - Symptomatic intracerebral haemorrhage defined by source trial   
 
